Generic drug
Medroxyprogesterone price, strengths & recalls
Generic of Depo-Provera, depo-subQ provera
Pharmacies pay $4.58 for 30 tablets of Medroxyprogesterone 10 mg tablet this week, and from $3.45 to $26.90 across its 5 priced strengths and forms. 23 manufacturers make it. It is in shortage (being discontinued). 5 recalls are ongoing. Its official label last changed on July 24, 2024.
Being discontinued5 open recallsGeneric- Fair cash price
- $15.77
- Strengths
- 5
- Makers
- 23
- Updated
- Nov 11
Medroxyprogesterone price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 150 mg/mL, 1 mL injection | $17.86 | $17.86 / 1 mL |
| 150 mg/mL, 1 mL prefilled syringe | $26.90 | $26.90 / 1 mL |
| 2.5 mg tablet | $0.1149 | $3.45 / 30 tablets |
| 5 mg tablet | $0.1395 | $4.18 / 30 tablets |
| 10 mg tablet | $0.1526 | $4.58 / 30 tablets |
The lowest cost per tablet is 2.5 mg tablet at $0.1149. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Brand names of medroxyprogesterone
A brand and its generic share the active ingredient; the generic is almost always far cheaper.
Supply status: shortages & recalls
Shortages
- PROVERA, Tablet, 10 mg (NDC 0009-0051-01)Discontinuation of the manufacture of the drug; Withdrawal from sale expected September 2026.
- PROVERA, Tablet, 2.5 mg (NDC 0009-0065-01)Discontinuation of the manufacture of the drug; Withdrawal from sale expected early October 2026.
In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.
Recalls
Showing the 6 most relevant of 33 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Medroxyprogesterone
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
MedroxyPROGESTERone Acetate Tablets, USP
WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA FOR ESTROGEN PLUS PROGESTIN THERAPY
Cardiovascular Disorders and Probable Dementia
Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia. (See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders and Probable Dementia.)
The Women's Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo. (See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders.)
The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women. (See CLINICAL STUDIES and WARNINGS, Probable Dementia and PRECAUTIONS, Geriatric Use.)
Breast Cancer
The WHI estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer. (See CLINICAL STUDIES and WARNINGS,Malignant Neoplasm,Breast Cancer.)
In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA, and other combinations and dosage forms of estrogens and progestins.
Progestins with estrogens should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA011839 · Pfizer
- First approved
- June 18, 1959 (67 years ago)
- Latest approved change
- February 15, 2024
- Approved label
- PDF, Feb 20, 2024
- Generic makers
- 10 approved generic applications on the market
Medroxyprogesterone questions
How much does medroxyprogesterone cost without insurance?
Pharmacies pay about $4.58 for 30 tablets of medroxyprogesterone 10 mg tablet ($0.1526 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $15.77. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
What is the brand name of medroxyprogesterone?
Medroxyprogesterone is sold as Depo-Provera, depo-subQ provera. The generic has the same active ingredient and usually costs far less.
Is medroxyprogesterone in shortage?
Yes. 2 products are listed as in shortage or being discontinued (being discontinued). See which ones.
Has medroxyprogesterone been recalled?
33 recalls on record, 5 ongoing. Recalls name specific lots - check yours.
When did the medroxyprogesterone label last change?
The official label was last updated on July 24, 2024 (version 1012). See what changed.
Talk about medroxyprogesterone
No comments yet. Questions, tips, what worked for you - start the conversation.